Market Research Reports, Inc. has announced the addition of “PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023” research report to their offering. See more at- http://mrr.cm/ZQQ
2. www.MarketResearchReports.com
Introduction to Report
Launch Date: March 31, 2014
Number of Pages: 278
Geography Coverage: Global
Available Format: PDF
Price For Single User License: USD 9,995
Price For Site License: USD 1,990
Price For Global User License: USD 29,985
Delivery Time: Within 24 Hours (During Working Days)
3. www.MarketResearchReports.com
About the Report
The migraine market is saturated with generic drugs, and
the remaining branded products already on the market
are expected to lose exclusivity during the next few years,
with the exception of Botox for chronic migraine, which is
expected to maintain its leading position in terms of sales.
However, reformulations of mature products as well as
new classes of therapies are anticipated to launch during
the forecast period and these will contribute to the
market growth. By 2023, the migraine market will grow to
$3.7 billion at a compound annual growth rate (CAGR) of
3.6%, with the US continuing to dominate the market as a
result of higher drug prices and a large migraine
population.
4. www.MarketResearchReports.com
Research Findings
The global migraine treatment market value is expected to
undergo a modest increase over the coming years, climbing from
$2.5 billion in 2012 to $3.7 billion by 2023, at a Compound
Annual Growth Rate (CAGR) of 3.6%, according to a new report
from research and consulting firm by Publisher.
The company’s latest report states that out of the seven major
markets (7MM: the US, France, Germany, Italy, Spain, the UK
and Japan), the US dominated the migraine space in 2012 with a
global share of 77%. It will maintain its market-leading position
by 2023, with a higher share of 84%.
Teva and NuPathe’s Zecuity, the first and only iontophoretic
transdermal system for migraine, will prove popular among the
population that requires or prefers an alternative route of
administration over the existing formulations of acute
treatments. We expect the therapy to achieve sales of
approximately $180.5 million by 2023.
We forecast that CoLucid’s lamiditan and Merck’s MK-1602
combined sales will reach nearly $1.3 billion by 2023
5. www.MarketResearchReports.com
Research Findings Continues..
The main driver of the expansion of the migraine market will be
the continuous use of Botox for chronic migraine. The
introduction of reformulations of mature products as well as
new classes of therapies will further increase the market size.
The biggest barrier for the introduction of new therapies will be
patent expirations of the majority of the drugs marketed for
migraine, which have resulted in an increase of generics, and
which may negatively impact revenue from branded drugs that
are expected to launch in the forecast period.
The concerns of reducing healthcare costs as part of
government austerity measures, particularly in Europe, which
will impede market growth. To ensure reimbursement
companies will have to work closely together with payers and
price their drugs competitively.
6. www.MarketResearchReports.com
Report Coverage
1. Introduction
2. Disease Overview
3. Epidemiology
4. Disease Management
5. Competitive Assessment
6. Opportunity and Unmet Need
7. Pipeline Assessment
8. Current and Future Players
9. Market Outlook
10.Appendix
For more details regarding Report coverage see the last slide
All logos and Images mentioned on this slide belong to their respective owners.
7. www.MarketResearchReports.com
Company Coverage
1. GlaxoSmithKline
2. AstraZeneca
3. Merck
4. Vernalis
5. Almirall
6. Pfizer
7. Zogenix
8. NuPathe
9. Allergan
10.RedHill Biopharma
11.OptiNose
12.CoLucid Pharmaceuticals
13.SUDA
14.Revance Therapeutics
15.NeurAxon
For more details regarding Report coverage see the last slide
All logos and Images mentioned on this slide belong to their respective owners.
8. www.MarketResearchReports.com
Custom Research:
Are you an industry professional, entrepreneur,
venture capitalist, investors and organization, then let
us know your specific research requirements. Our goal
is to cater to your requirements be it for a custom
market research project, syndicated research report on
a specific market or industry sector, newsletter creation,
case study development or anything else related to
marketing research.
For Any Customization Related query Visit IdeaCenter @
http://www.marketresearchreports.com/idea-center
9. www.MarketResearchReports.com
How To Buy This Report?
Visit following URL to see Table of Content and
purchase this publication:
http://mrr.cm/ZQQ
About Market Research Reports, Inc.
Market Research Reports provides a customized set
of reports from reputed Publishers, built on the
intelligence available within organizations and
leverages on our motto of “Intelligence Redefined”.
Contact : Amitava Sen
Email : info@marketresearchreports.com
Phone: +1 302-703-7787 (USA) +91-8762746600 (India)